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down’ (e.g. start with a combination of biological and immu-
nosuppressant and ‘de-escalate’ if possible) or ‘step-up’ 
treatment (e.g. start with topical steroids, step up to system-
ic steroid, go to immunosuppression and biologicals if nec-
essary) may be better. In general, in an upcoming era of in-
dividualized and personalized medicine, a ‘one-size-fits-all’ 
approach does not appear to be desirable. CD patients defi-
nitely should not be undertreated (which is still frequently 
the case) or remain on steroid treatment (which is inappro-
priate); however, overtreatment (putting patients at risk of 
side effects without benefit) is against a fundamental prin-
ciple of medicine: nihil nocere (do no harm). 
 Copyright © 2013 S. Karger AG, Basel 
 What Does ‘Step Up’ Mean for Crohn’s Disease 
Therapy? 
 Usually the term ‘step-up’ treatment in Crohn’s dis-
ease (CD) refers to a more traditional approach of thera-
py: for a newly diagnosed patient suffering from CD, first 
an approach is used that has a relatively lower risk of (se-
vere) side effects. The choice of therapy is based on ‘the 
balance between drug potency and potential side-effects; 
previous response to treatment … and the presence of 
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 Abstract 
 In recent years, a change in the treatment goals for patients 
with Crohn’s disease (CD) has come under intense discus-
sion. Whereas 10 years ago treatment was initiated mainly in 
reaction to acute flares of the disease aimed to improve clin-
ical symptoms, the focus now has changed to the prevention 
of damage to the intestinal wall. The prevention of structur-
al damage by achievement of ‘mucosal healing’, however, is 
associated with the more ‘aggressive’ treatment and an ear-
lier use of immunosuppressants and biologicals. The use of 
immunosuppressants and biologicals especially in patients 
with CD has decreased the rates of surgery and hospitaliza-
tions, indicating that there is a group of patients definitely 
profiting from such an early use of immunosuppressive 
treatment. In this group of patients, the benefits outweigh 
the disadvantages of immunosuppression: the increased 
risk of severe infections. However, it remains questionable 
whether this improvement can only be achieved by com-
pletely reversing established treatment strategies. The dis-
pute has been condensed to the questions whether ‘top-
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extraintestinal manifestations or complications’ as stated 
in the ECCO guidelines  [1] .
 As obvious from Cochrane reviews and meta-analyses, 
the benefit of sulfasalazine and 5-aminosalicylic acid (5-
ASA) preparations in uncomplicated CD is quite limited 
 [2–4] . In a meta-analysis of three double-blind random-
ized studies on the role of 5-ASA in the treatment of active 
CD, 4 g/day 5-ASA was superior to placebo in reducing the 
Crohn’s disease activity index (CDAI); however, the clini-
cal effect was not convincing  [4, 5] . Nevertheless, even new 
treatment guidelines still suggest to test a short course of 
sulfasalazine in colonic CD and not to exclude 5-ASA use 
in mild ileocecal disease (‘the benefit of mesalazine is lim-
ited’)  [1] . In population-based studies, such as the IBSEN 
cohort, there is a significant amount of CD patients that 
only received treatment with 5-ASA and never needed ste-
roids  [6, 7] . Interpretation of those data is debatable.
 There is better evidence for the use budesonide in 
mild-to-moderate flares of CD as the next step of treat-
ment  [1, 8–11] : 9 mg budesonide per day is effective and 
superior to treatment with 5-ASA  [1, 8] for the induction 
of remission in CD patients. Budesonide will induce re-
mission in 51–60% of the patients within 8–10 weeks  [1, 
8–11] . Mucosa healing is achieved in only 24% of treated 
patients  [12] . The treatment is associated with limited 
side effects. Typical glucocorticoid-associated side effects 
are less frequent as compared to systemic glucocorticoid 
treatment  [9, 11, 13–15] . In patients with high disease ac-
tivity and/or combined disease location in the ileum and 
colon, 18 mg budesonide per day is more effective; how-
ever, systemic side effects become apparent more fre-
quently  [16] .
 In more severe disease, the next step up would be the 
administration of systemic glucocorticoids. By a predni-
sone/prednisolone treatment with 100 mg/day, remission 
can be achieved within 6 weeks in up to 92% of patients 
 [17, 18] .
 In a systematic Cochrane review on the efficacy of con-
ventional corticosteroids, the authors identified two stud-
ies that compared corticosteroids to placebo and six stud-
ies that compared corticosteroids to 5-ASA  [18] . Cortico-
steroids were found to be significantly more effective than 
placebo at inducing remission in CD  [18] . In short-term 
intervention with steroids, the number of adverse events 
did not differ between the glucocorticoids and high-dose 
5-ASA  [18] . Furthermore, glucocorticoids were not asso-
ciated with more study withdrawals due to adverse events 
than placebo or 5-ASA  [18] . This indicates that steroids 
are relatively safe and well tolerated for the treatment of 
acute flares of CD.
 In a ‘classical step-up approach’ in patients not re-
sponding to steroids (steroid-refractory) or in which ste-
roids cannot be tapered (steroid-dependent), immuno-
suppressants [azathioprine (AZA); 6-mercaptopurine
(6-MP); methotrexate (MTX)] or biologics (infliximab, 
adalimumab, certolizumab pegol) may be used  [1] . AZA 
(2–2.5 mg/kg body weight/day) and/or 6-MP (1.0–1.5 
mg/kg body weight/day) have been shown to be effective 
immunosuppressants in inflammatory bowel disease 
(IBD)  [19] . Near-complete mucosa healing has been re-
ported in up to 83% of patients  [12] . MTX is a suitable 
alternative (25 mg parenterally/once weekly)  [20] .
 If a rapid treatment response is desired or if no remis-
sion can be achieved with AZA/6-MP/MTX, treatment 
with antibodies against TNF (infliximab, adalimumab, 
certolizumab) is associated with a success rate in up to 
60–70% of the patients  [21–25] . About 60% of the pa-
tients who respond initially will achieve long-term remis-
sion  [26–29] . There is a certain rate of secondary loss of 
response that is similar for all anti-TNF products  [30–35] . 
The different antibodies differ slightly in their therapeutic 
efficacy  [36] .
 In contrast to studies that are based on single-center 
experience or data from large hospitals in population-
based cohorts, around 50% of patients with CD are re-
ported to have been treated with corticosteroids  [37] . In 
a population-based cohort from Olmsted County, it was 
reported that more than one third of CD patients achieved 
remission with a treatment ‘one step below’ systemic glu-
cocorticoids  [37] . This indicates that a group of CD pa-
tients (which may usually not be seen at referral centers) 
requires only mild therapy. From several population-
based cohorts (Olmstead County, IBSEN) it may be con-
cluded that 30–50% of patients will require immunosup-
pression. Of those, about 50 or 15–25% of the total CD 
population will not be sufficiently treated with purine an-
alogs  [38, 39] . These patients will need to step up to anti-
TNF therapy.
 What Does ‘Top Down’ Mean in CD Therapy? 
 The term ‘top down’ in the context of CD therapy 
means that biologicals and immunosuppressants are ap-
plied right after the diagnosis of CD as a first-line therapy. 
The ‘character’ of the disease (whether it is mild disease 
with low activity and infrequent flares, aggressive disease 
with frequent flares, or chronic active inflammation) is 
not further evaluated as this would further require some 
weeks or months.
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 The rationale for such an approach comes from rheu-
matology where an early intervention with biologicals is 
thought to be ‘disease-modifying’, e.g. preventing pro-
gressive destruction of joints  [40] . In reality, of course, 
not all rheumatologic patients are treated top down.
 With the top-down approach, one important question 
remains: What can we do with the 40% of patients that 
don’t come into remission as we know from the SONIC 
study  [41] and other trials, the so-called ‘primary non-
responders?’  [27, 42] . The use of a second or even a third 
anti-TNF drug may eventually be effective  [43, 44] ; how-
ever, patients failing a first anti-TNF antibody are less 
likely to achieve remission with a second anti-TNF agent 
[ 44 ]. Another question that arises is how to maintain re-
mission in those patients. In the STORI trial, a stopping 
strategy and criteria for therapy discontinuation have 
been provided  [45] . In a prospective approach in 115 pa-
tients with CD that had been treated for at least 1 year 
with infliximab and thiopurines and had been in remis-
sion for more than 6 months, infliximab was stopped and 
thiopurine therapy maintained  [45] . The relapse rate after 
1 year was reported to be 44%. Risk factors for a relapse 
were increased leukocyte counts, decreased hemoglobin 
levels, increased CRP and fecal calprotectin, as well as ab-
sence of mucosal healing  [45] . In the patients experienc-
ing a relapse, retreatment with infliximab was effective in 
88%  [45] .
 Whereas it is now generally accepted that anti-TNF 
therapy should be administered on a regular basis (‘sched-
uled treatment’) as this reduces the risk for the formation 
of neutralizing antibodies, loss of response and allergic 
reactions unfortunately in the ‘top-down – step-up’ study 
by D’Haens et al. [46] , infliximab was given more or less 
‘on demand’ after induction therapy.
 Unfortunately the ‘step-up’ and ‘top-down’ approach 
are frequently discussed as exclusive alternatives indicat-
ing that either the one or the other strategy should be fol-
lowed. In contrast, it appears to be reasonable to identify 
a population that is at high risk of a severe and damaging 
disease course that will profit from a more aggressive ap-
proach with high probability. For those patients, the risk/
benefit ratio certainly would indicate a benefit for ‘top 
down’ in the long run, whereas the risk/benefit ratio will 
have an imbalance to the risk side for a CD patient popu-
lation with a mild disease course and low risk of compli-
cations. An additional negative impact on this discussion 
is that even in manuscripts that favor ‘top-down’ therapy 
only for such risk populations, general assumptions on 
CD are made (e.g. the conventional ‘step-up’ treatment 
approach does not alter the natural history of the disease, 
which obviously is wrong as the ‘natural’ history would 
be without intervention) that indicate an advantage of 
‘top-down’ treatment for the whole CD patient popula-
tion.
 What Assumptions Are the Bases of the Discussion 
of ‘Top Down’ versus ‘Step Up’? 
 What are the assumptions put forward to support a 
top-down approach in CD therapy? The most important 
assumptions made in favor of a top-down approach are 
depicted in  table 1 . It is stated that top-down treatment 
is disease-modifying, meaning that the ‘natural course’ 
of CD is changed. It may be argued that any therapy will 
change the ‘natural course’ of a disease, if ‘natural’ means 
the disease course without any intervention. It is obvious 
that some difficulties in the interpretation of the assump-
tion that top-down treatment is disease-modifying is 
caused by the unclear meaning of ‘natural’ disease course. 
The term has been adopted from rheumatology. How-
ever, nonbiological therapy may also prevent joint de-
struction to some extent even in rheumatology. A further 
argument for a top-down approach is that top-down 
treatment induces mucosal healing more frequently. 
When compared to other drugs, this is certainly the case. 
Obviously, top-down treatment has the highest chance 
of inducing mucosal healing. However, we are still far 
from achieving mucosal healing in the majority of ini-
tially treated patients. Being ‘better’ still could mean that 
an attempt to achieve mucosal healing can be undertaken 
with other drugs, but in case of failure it may be switched 
to a biological. This is currently being investigated in the 
CALM trial, which is a very important clinical study. 
Achieving more often mucosal healing subsequently is 
not a very good argument for a top-down approach. The 
next argument for a top-down approach is that top-down 
treatment induces long-term remission. This, however, 
would only be a relevant argument if the same combina-
tion of drugs (i.e. biologicals and immunosuppressants) 
would not achieve long-term remission in a step-up ap-
Table 1.  Arguments for a top-down treatment in patients with CD
– Top-down treatment is disease-modifying
– Top-down treatment induces mucosal healing more frequently
– Top-down treatment induces long-term remission
– Step-up treatment has significant disadvantages
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proach. A final argument for top down is that step-up 
treatment has significant disadvantages such as more 
days off work and more days of physical impairment and 
reduced quality of life.
 Those arguments of course are to some extent inter-
related and not completely separate or different. If the 
top-down treatment induces mucosal healing more fre-
quently, then it will likely be associated with better remis-
sion rates and better long-term remission. A CD patient 
in long-term remission will experience less intestinal 
damage. Therefore, this would indeed be of great influ-
ence on the disease course.
 Pariente et al.  [47] summarized this concept in an in-
triguing graph ( fig. 1 ). If we only monitor the clinical ac-
tivity of CD (as it is still recommended in many guide-
lines), there may be subclinical disease activity causing 
damage to the intestinal mucosa or the intestinal wall. In 
the original figure by Pariente et al., surgery always caused 
more damage to the gut indicating that it should be avoid-
ed under any circumstances. Clinical reality argues 
against that. Only major resective surgery will cause ad-
ditional damage to the intestine. Stricturoplasty or small 
resective surgery, fistula surgery, or abscess drainage will 
improve intestinal function and reduce the ‘digestive 
damage’. We need to be fair with our surgical colleagues 
at that point. Therefore, it is necessary to modify this 
scheme to better reflect clinical reality ( fig. 1 ).
 What Evidence Do We Have to Support a ‘Top-Down’ 
Approach? 
 There are some good arguments for early use of im-
munosuppressants or biologicals in a subgroup of CD pa-
tients. Most of the arguments, however, are of an indirect 
nature.
 Indirect Evidence 
 With respect to clinical remission, subjects ran-
domized to adalimumab in CHARM who enrolled in 
ADHERE were analyzed in an intention-to-treat ap-
proach with respect to treatment efficacy in relation to 
disease duration  [48] . The analysis was strict as subjects 
who moved to open-label therapy in CHARM were clas-
sified as nonremitters from that point forward  [48] . Sub-
jects who moved to every-week therapy during ADHERE 
were also classified as nonremitters from that point for-
ward. Furthermore, missing data were classified as non-
remission. With those strict criteria, 55% of the patients 
with a CD duration of less than 2 years achieved a remis-
sion 58 weeks after CHARM baseline, whereas only 40% 
or less of patients that suffered from CD for 2–5 years or 
more than 5 years were in remission (CDAI <150)  [48] . 
This difference was still obvious 164 weeks after the 
CHARM baseline, but less pronounced  [48] .
 Besides clinical remission rates, mucosal healing has 
been analyzed in detail. In the SONIC trial, early anti-
TNF-based therapy was associated with sustained ste-
roid-free remission and complete mucosal healing  [41] . 
In SONIC, AZA was compared to infliximab and the 
combination of both, a situation that cannot be directly 
compared to a top-down versus step-up situation.
 In the above-mentioned top-down versus step-up 
study by D’Haens and colleagues  [49] , clinical remission 
rates were similar at week 104, but mucosal healing rate 
was higher with early anti-TNF therapy as compared to 
step-up therapy. In those patients, mucosal healing was a 
strong predictor of steroid-free remission  [49] . In the 
STORI study performed by the GETAID, mucosal heal-
ing predicted maintenance of clinical remission when an-
ti-TNF therapy was discontinued  [45] . In the EXTEND 
trial, early anti-TNF use was associated with a higher rate 
of mucosal healing than later use  [50] . This is in line with 
earlier reports indicating that anti-TNF antibodies in-
duce mucosal healing more effectively in comparison to 
steroid therapy or immunosuppression  [51–53] . Patients 
achieving mucosal healing have better long-term disease 
courses in population-based cohorts as seen in the IBSEN 
study  [6] .
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 Fig. 1. Disease courses in CD. Clinical activity may not reflect on-
going intestinal damage. Inflammation may be subclinical and re-
sult in cumulative tissue damage. Surgery may add additional tis-
sue damage and loss of function, or may restore function and re-
duce damage at least partially (modified according to  [47] ). 
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 Direct Evidence 
 One of the first trials investigating early treatment of 
IBD was the trial by Markowitz et al. [54] in pediatric pa-
tients who received 6-MP right after the diagnosis of IBD. 
In a prospective placebo-controlled multicenter trial, the 
combination of 6-MP (or placebo) and prednisone as 
therapy for 55 children with newly diagnosed moderate-
to-severe CD was evaluated. In the 6-MP group, the dura-
tion of steroid use was significantly shorter and the cu-
mulative steroid dose was significantly lower. Remission 
was induced in 89% of both groups, but only 9% of the 
6-MP group relapsed compared with 47% of the placebo 
controls. Markowitz and colleagues concluded that early 
immunosuppression with ‘6-MP should be part of the  ini-
tial treatment regimen for children with newly diagnosed 
moderate-to-severe CD’, which reflects a top-down ap-
proach.
 The most important argument for a top-down treat-
ment is the clinical trial published by D’Haens et al. [46] 
in  The Lancet . They assessed the success rates of a top-
down versus a step-up therapy in ‘newly diagnosed’ CD 
of less than 4 years’ duration (n = 129)  [46] . The patients 
had to be naïve to immunomodulators and biologicals. 
The top-down group (n = 65) received AZA and infli-
ximab in weeks 0, 2 and 5 and then later the anti-TNF in 
an ‘on-demand’ strategy. The step-up group (n = 64) re-
ceived steroids as a first-line therapy, AZA or MTX in a 
second step and infliximab as a third-line therapy. The 
coprimary endpoints (CDAI <150  and no steroids  and no 
surgery) were significantly different for both groups at 
weeks 24 and 52; however, there was no difference at week 
80 and 104  [46, 49] . At the end of the observation period, 
the relative amount of patients receiving infliximab did 
not significantly differ and was around 20%  [46, 49] . 
However, by definition the amount of patients receiving 
immunosuppressants was up to 100% in the top-down 
group, whereas it was around 80% in the step-up group, 
which indicates that in 20% of patients steroids induced 
a long-lasting remission without further need of escala-
tion of therapy  [46, 49] .
 Mucosal healing was significantly more frequent in the 
top-down group in 71% of patients, whereas it was only 
achieved in 30% of the step-up patients.
 Weighing the Value of Top-Down Therapy 
 The benefits of a top-down approach according to the 
above-mentioned data are rather clear. There seems to be 
a better maintenance of remission after achieving it. 
Bowel function is more rapidly improved, which is asso-
ciated with an earlier improvement of the quality of life. 
The earlier promotion of mucosal healing may prevent 
complications such as perforations and obstructions 
 [55–57] .
 On the other hand, there are also significant disadvan-
tages of a top-down approach if applied to all patients 
without selecting those at risk for a complicated disease 
course. There are significant side effects of a more aggres-
sive therapy to consider. The costs raised by a top-down 
approach for every CD patient would be significant and 
no health care system could cover such a strategy, making 
it unrealistic in the end. The majority of patients may not 
require more potent treatment, at least initially.
 With this in mind we also should consider the data 
from the Norwegian population-based IBSEN study  [6] . 
The investigators identified four primary courses of CD 
and asked 197 patients to identify which curve best 
matched their disease course over the 10 years since diag-
nosis  [6] . As these four distinct disease courses suggest, 
no single management plan will suit all patients. CD man-
agement must therefore be tailored to the individual pa-
tient.
 The IBSEN study data suggest that 43% of patients 
may have a mild disease course and not require intensive 
therapy  [6] (fig. 2). However, the majority of patients is 
likely to have chronic disease and may benefit from early 
intensive management.
50% without need of steroids
(5-ASA, surgery, other treatments)ҭ
>10% need for
biologicals and
further therapy
25% remission upon steroidsҭ
15% remission upon
AZA/6-MP
 Fig. 2. Need for therapies among CD patients in population-based 
cohorts. 
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 Would an ‘Accelerated Step-Up Treatment’ Cause a 
Disadvantage and Damage to IBD Patients? 
 A very important question with respect to a decision 
between the top-down or step-up approach is whether a 
step-up approach would indeed mean a significant disad-
vantage for the patient as mentioned above. Cosnes et al. 
[58] compared accelerated step-up care with early or im-
mediate start of immunosuppressants (early AZA, n = 66) 
with conventional step-up therapy (n = 68) in patients 
with CD. The randomized open-label controlled trial was 
conducted in 24 centers between 2005 and 2010. The aim 
of this study was to compare the accelerated step-care 
strategy in patients with early CD and predictors of dis-
abling disease (age at diagnosis <40, steroid use at first 
flare, perianal disease) with conventional therapy using 
steroids for the flare. Interestingly (in contrast to the Mar-
kowitz study in children), early AZA use in patients at high 
risk for disabling disease had no significant impact on the 
subsequent 3-year CD course  [58] . Sixty-two percent of 
those CD patients assigned to the on-demand AZA group 
required AZA after a median follow-up of 5.6 months. No 
significant differences were found between the two groups 
with respect to time spent in remission. Among the pa-
tients receiving early AZA (‘top down’), 29% required ad-
ditional treatment with anti-TNF agents, similar to 26% in 
the steroid first/on-demand group who needed additional 
anti-TNF treatment. There was a trend to higher rates of 
unplanned perianal surgery in the steroid-treated patients. 
A similar trend was observed for intestinal surgery: 11% of 
those who received early AZA and 21% of patients who 
started with steroids in the ‘classical step-up’ approach re-
quired intestinal surgery without statistical significance 
between the groups (which could indicate that the study 
was not sufficiently powered). CDAI and CRP scores were 
not different between the groups  [58] .
 The authors mention that conventional therapy could 
allow the patient to be vaccinated before immunomodu-
lator therapy  [58] . Overall, the step-up approach (which 
still was an ‘accelerated’ approach applying immunosup-
pressant after a first failed steroid course) had no signifi-
cant disadvantage in this setting. It is important to note 
that the authors tried to select patients with early disease 
and high risk for complicated disease course. Neverthe-
less, at the end of the study more than one third of the 
patients in the step-up group had not met the criteria for 
requiring AZA  [58] .
 Indirect evidence also comes from another study. Sor-
rentino et al.  [59] investigated whether infliximab, not 
given immediately after surgery to prevent recurrence of 
CD but immediately after detection of postoperative en-
doscopic recurrence, could induce endoscopic remission 
at 54 weeks. Forty-three patients with ileocolonic CD and 
ileocecal resection were included and underwent colo-
noscopy 6 months after surgery. Twenty-four out of 43 
patients had an endoscopic recurrence at 6 months. Thir-
teen were treated with infliximab, out of which 54% 
achieved endoscopic remission at 54 weeks and none had 
clinical recurrence. Again this study may be underpow-
ered to detect a disadvantage of the delayed therapy and 
the observation period may be too short. In the study re-
ported by Regueiro et al. [60] , the rate of endoscopic re-
currence at 1 year was only 9% (1 of 11 patients). This 
could indeed indicate a benefit from a ‘top-down’ ap-
proach in this situation. However, at the moment we do 
not have clear evidence indicating that ‘accelerated step-
up’ upon demand is of disadvantage even for patients at 
some risk for complicated disease course.
 Summary 
 A significant number of patients would be overtreated 
if a top-down therapy approach would be recommend for 
all patients diagnosed with CD (fig. 2). This would put 
patients with a mild and uncomplicated disease course at 
an unnecessary risk for therapy side effects and complica-
tions. Furthermore, there is no scientific evidence that an 
‘accelerated step-up’ treatment (within the first or the 
first 2 years of disease) is of any disadvantage for the CD 
patient that develops a more severe disease. Most post hoc 
analyses in the respective anti-TNF trials indicating a bet-
ter treatment effect in ‘early’ disease usually looked at a 
group that had the disease for 2 years or less  [61] .
 In an area in which – with good reasons – we favor an 
individualized therapy as well as personalized medicine, a 
top-down approach for all CD patients is displaced. A ‘one-
size-fits-all’ therapy principle only reflects a nonpersonal-
ized and nonindividualized therapy approach. Either we 
are able to detect better predictors of CD disease course or 
we only apply a top-down therapy to the patient group at 
high risk for complications. A step-wise (but nevertheless 
rapid) therapy escalation can take individual patient prefer-
ences and needs into account. A timely progression from 
ineffective therapy to the next step of treatment is manda-
tory to avoid disadvantages. This needs to be based on up-
to-date knowledge and clinical trials. Subsequently, careful 
patient selection will certainly justify the top-down ap-
proach in a subgroup of CD patients. However, the selec-
tion criteria need to be further investigated and improved.
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